Drug & supplement interaction

Cannabidivarin (cbdv) + Upadacitinib Hemihydrate

Upadacitinib Hemihydrate brand name: Rinvoq.

No Known Interaction
The bottom line No known interaction

We found no known interaction between Cannabidivarin (cbdv) and Upadacitinib Hemihydrate in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.

Know someone taking this? Share
Interaction report

Cannabidivarin (cbdv) and Upadacitinib Hemihydrate

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between Upadacitinib Hemihydrate and Cannabidivarin (cbdv) in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

Worth understanding: our licensed dataset holds no drug-interaction record for Cannabidivarin (cbdv) at all — not against Upadacitinib Hemihydrate, and not against any other medication we track. This verdict therefore rests on the absence of any recorded data, not on research that looked at this combination and found nothing. We cannot rule an interaction out.

If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Cannabidivarin (cbdv) safety at a glance

Cannabidivarin (cb... overall Not established Human safety data are very limited, so long-term effects are not well understood.
Pregnancy Avoid There is not enough safety information, so it is best avoided during pregnancy.
Breastfeeding Avoid Safety while breastfeeding is unknown, so avoid use.

Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining Upadacitinib Hemihydrate and Cannabidivarin (cbdv)? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
What to actually watch for

No Interaction Found — But Data Suggests Cannabidivarin (cbdv) and Upadacitinib Hemihydrate May Share Several of the Same Side Effects

This is not an interaction. Neither one changes how your body handles the other, and nothing here says they react together. What our sources do show is that each has separately been linked to the effects below — so taking both can make those effects more likely to turn up, and harder to pin on one or the other if they do.

  • Stomach pain / Nausea Additional detail

    Cannabidivarin (cbdv)

    “Orally, cannabidivarin has been associated with diarrhea, nausea, and abdominal pain. Drooling has been reported in one child with Rett syndrome.”

    Cannabidivarin (cbdv) · Natural Medicines adverse-effect record, reported in diarrhea.

    2 sources cited
    1. 107343. Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res 2021;6(6):528-536. PubMed
    2. 110246. Hurley EN, Ellaway CJ, Johnson AM, et al. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia 2022;63(7):1736-1747. PubMed

    Upadacitinib Hemihydrate

    Listed in the ADVERSE REACTIONS section of the FDA label for Upadacitinib Hemihydrate. Read the label on DailyMed ›

  • A skin rash Additional detail

    Cannabidivarin (cbdv)

    “Orally, cannabidivarin 800 mg twice daily has been associated with maculopapular rash. The rash resolved with discontinuation of cannabidivarin.”

    Cannabidivarin (cbdv) · Natural Medicines adverse-effect record, reported in myasthenia gravis.

    1 source cited
    1. 107343. Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res 2021;6(6):528-536. PubMed

    Upadacitinib Hemihydrate

    Listed in the ADVERSE REACTIONS section of the FDA label for Upadacitinib Hemihydrate. Read the label on DailyMed ›

  • Headache Additional detail

    Cannabidivarin (cbdv)

    “Orally, cannabidivarin has been associated with dizziness, somnolence, and headache. Ataxia, confusion, and dysarthria have been reported in one patient in a clinical trial who had been taking cannabidivarin 800 mg twice daily for 30 days. This patient also experienced other symptoms of intoxication, including arterial hypotension, nystagmus, diplopia, and elevated liver transaminases.”

    Cannabidivarin (cbdv) · Natural Medicines adverse-effect record, reported in cluster headache.

    2 sources cited
    1. 107343. Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res 2021;6(6):528-536. PubMed
    2. 110246. Hurley EN, Ellaway CJ, Johnson AM, et al. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia 2022;63(7):1736-1747. PubMed

    Upadacitinib Hemihydrate

    Listed in the ADVERSE REACTIONS section of the FDA label for Upadacitinib Hemihydrate. Read the label on DailyMed ›

Reported for Cannabidivarin (cbdv) but not commonly for Upadacitinib Hemihydrate: kidney problems, low blood pressure, drowsiness and dizziness.

Effects for Upadacitinib Hemihydrate come from the ADVERSE REACTIONS section of its FDA label; effects for Cannabidivarin (cbdv) come from the Natural Medicines adverse-effect record, quoted above. Wording is matched across sources by our own clinical vocabulary, so treat this as a prompt to pay attention, not a diagnosis.

Overlapping uses

What Upadacitinib Hemihydrate Is Prescribed For, and What Cannabidivarin (cbdv) Has Been Studied For

These two come up together because they touch the same health topic — not because they do the same job. Upadacitinib Hemihydrate is a prescription medicine with approved uses on its FDA label. Cannabidivarin (cbdv) is a supplement: what follows is what researchers have looked at it for, and how strong that evidence is.

Upadacitinib Hemihydrate is prescribed for: Upadacitinib is approved for adults and some children with moderate-to-severe inflammatory conditions when other treatments haven't worked well enough. It targets overactive immune signaling that drives these diseases. Conditions it treats include:Rheumatoid arthritis (RA) — in adults who didn't respond to TNF blocker medications Psoriatic arthritis — in adults and children 2 years and older who didn't respond to TNF blockers Atopic dermatitis (eczema) — in people 12 and older whose disease isn't controlled by other systemic therapies Ulcerative colitis — in adults who didn't respond to TNF blockers or other approved therapies Crohn's disease — in adults who didn't respond to TNF blockers or other approved therapies

Cannabidivarin (cbdv) has been studied for:

  • Ulcerative colitis studied, not established Cannabidivarin (cbdv) has been studied for this. Natural Medicines rates the evidence: Insufficient Reliable Evidence To Rate Read what the research shows

    Cannabidivarin (cbdv) for ulcerative colitis

    Although there is interest in using oral cannabidivarin for ulcerative colitis, there is insufficient reliable information about the clinical effects of cannabidivarin for this condition.

Effectiveness ratings and the research summaries above are the verbatim record from the Natural Medicines database, which grades evidence from “Effective” down to “Insufficient Reliable Evidence To Rate”. A rating below the top of that scale means researchers have looked at it — not that it works, and never that it can stand in for a prescribed medicine. Do not stop or replace Upadacitinib Hemihydrate on your own; if you are taking Cannabidivarin (cbdv) for the same health topic, tell your prescriber, especially if the medicine is being adjusted to a target.

Everything else you take

See Every Supplement That Interacts With Upadacitinib Hemihydrate

This page covers Cannabidivarin (cbdv) only. If you take other supplements — a multivitamin, a sleep aid, something for joints — the Upadacitinib Hemihydrate page lists 138 supplements it has a documented interaction with, worst first, each one explained.

The most serious there right now: Activated Charcoal (major), Grapefruit (major), St. John's Wort (major), Acacia Rigidula (moderate) and Adrafinil (moderate).

By severity: 3 major · 94 moderate · 41 minor.

From our pharmacist’s overview on the Upadacitinib Hemihydrate page

“Grapefruit is the pairing I would want anyone on Rinvoq (upadacitinib) to know about first. The drug is cleared by a liver enzyme called CYP3A4, and grapefruit blocks that enzyme, letting blood levels climb, which matters for a medicine that already dials down the immune system.”

Reviewed by 2 · Jul 18, 2026

Open the Upadacitinib Hemihydrate interaction page

How much people look this up

Where Cannabidivarin (cbdv) and Upadacitinib Hemihydrate Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Cannabidivarin (cbdv)
Steady interest

#1,224 of 1,452 supplements looked up here in the last 7 days

29 days ago today
Medication Upadacitinib Hemihydrate
Top 25%

#320 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Cannabidivarin (cbdv) reference on this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified September 27, 2026. The Cannabidivarin (cbdv) and Upadacitinib Hemihydrate records this page draws on were last updated July 10, 2026.
  • What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
Data structure & sourcing designed and verified by .
Supplement

About Cannabidivarin (cbdv)

What is Cannabidivarin (cbdv)?

  • Epilepsy and seizures
  • Autism spectrum disorder
  • Rett syndrome
  • Fragile X syndrome
  • Nausea
  • Anxiety

Cannabidivarin (CBDV) is a non-intoxicating compound found in cannabis that is being studied mainly for epilepsy and certain neurodevelopmental conditions. The research is still early, mostly from laboratory and animal studies plus small human trials, so it is not an approved or proven treatment. Talk to your pharmacist or doctor before trying any CBDV product.

Cannabaceae · Compound derived from the flowers and leaves of the cannabis plant · Oils, tinctures, isolates, and research-grade formulations

An interaction check asks whether these two react with each other — it does not ask whether Cannabidivarin (cbdv) is a good idea for someone in your situation. Here is what our Cannabidivarin (cbdv) record says about it on its own.

Cannabidivarin (cbdv): dosing

There is no established standard dose for CBDV. The amounts used in research studies were chosen for those specific trials and are not the same as general supplement guidance.If you choose to use a CBDV product, follow the directions on the product label and start low.

From our Cannabidivarin (cbdv) monograph — the full record covers uses, side effects and every documented interaction.

Read the full Cannabidivarin (cbdv) monograph & all interactions
Medication

About Upadacitinib

What Is Upadacitinib Used For?

Brand name: Rinvoq

Upadacitinib is approved for adults and some children with moderate-to-severe inflammatory conditions when other treatments haven't worked well enough. It targets overactive immune signaling that drives these diseases.

Conditions it treats include:

  • Rheumatoid arthritis (RA) — in adults who didn't respond to TNF blocker medications
  • Psoriatic arthritis — in adults and children 2 years and older who didn't respond to TNF blockers
  • Atopic dermatitis (eczema) — in people 12 and older whose disease isn't controlled by other systemic therapies
  • Ulcerative colitis — in adults who didn't respond to TNF blockers or other approved therapies
  • Crohn's disease — in adults who didn't respond to TNF blockers or other approved therapies

See full Upadacitinib drug information
Keep checking

Other Drugs & Cannabidivarin (cbdv)

Browse every other medication we’ve checked against Cannabidivarin (cbdv) — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
0Moderate
0Minor
2,829No known interaction
No interaction 2,829 drugs checked — show the list
Evidence & sources

Cannabidivarin (cbdv) References

The 4 references that drive our Cannabidivarin (cbdv) monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

  1. European Medicines Agency. Public summary of opinion on orphan designation: Cannabidivarin for treatment of fragile X syndrome. Available at: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/18/1977-public-summary-opinion-orphan-designation-
  2. US Food and Drug Administration. Orphan Drug Designations and Approvals. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Accessed on March 19, 2021.
  3. Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res 2021;6(6):528-536. PubMed
  4. Hurley EN, Ellaway CJ, Johnson AM, et al. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia 2022;63(7):1736-1747. PubMed

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Taking Cannabidivarin (cbdv) and Upadacitinib Hemihydrate Together: Common Questions

Is it safe to take Cannabidivarin (cbdv) with Upadacitinib Hemihydrate?
We do not list a known interaction between Cannabidivarin (cbdv) and Upadacitinib Hemihydrate. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Do Cannabidivarin (cbdv) and Upadacitinib Hemihydrate have any of the same side effects?
Yes — our sources link each of them separately to 4 of the same effects. That is not an interaction: neither changes how your body handles the other. It does mean that if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
Are Cannabidivarin (cbdv) and Upadacitinib Hemihydrate used for the same thing?
They overlap in purpose, which usually means the real question is whether you need both rather than whether they are safe together. This page lists the shared uses and how strong the evidence is for Cannabidivarin (cbdv) in each. That is a conversation for your prescriber, especially if Upadacitinib Hemihydrate is being adjusted to a target.
Does Upadacitinib Hemihydrate interact with any supplements?
Yes. Upadacitinib Hemihydrate has documented interactions with 138 supplements in our database — Cannabidivarin (cbdv) is not one of them. The Upadacitinib Hemihydrate interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Still Have a Question About Upadacitinib Hemihydrate and Cannabidivarin (cbdv)?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.